Download PDF
Hamostaseologie 2020; 40(03): 311-321
DOI: 10.1055/a-1175-6530
Review Article
Georg Thieme Verlag KG Stuttgart · New York

The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and Challenges

Alice Trinchero
1   Center for Thrombosis and Hemostasis, University Medical Center Mainz, Johannes Gutenberg University, Mainz, Germany
2   Department of Clinical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland
,
Michelle Sholzberg
3   Hematology/Oncology, St. Michael's Hospital, Li Ka Shing Knowledge Institute, University of Toronto, Toronto, Ontario, Canada
,
Davide Matino
4   Department of Medicine, Hamilton, Ontario, Canada
5   Department of Medicine, McMaster University, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

12 February 2020

11 May 2020

Publication Date:
29 July 2020 (online)

Also available at
   Permissions and Reprints

Abstract

Hemophilia A (HA) and B (HB) are X-linked bleeding disorders caused by mutations in the F8 or F9 gene that result in the absence, or reduced activity, of the corresponding clotting factor. The severity of bleeding and related complications is proportional to the amount of residual circulating functional factor. The development of a safe and effective hemophilia treatment lasted several decades and has been mainly based on clotting factor replacement. Advances in the engineering and manufacturing of clotting concentrates have led to the widespread availability of extended half-life products that reduced the number of intravenous infusions needed to achieve adequate trough levels. The recent development of new nonfactor replacement treatments and biotechnology techniques has offered therapeutic alternatives for hemophilia patients with and without inhibitors. These are characterized by an easier route of administration, low immunogenicity, and, regarding gene therapy and cell-based treatments, potential long-term protection from bleeding after a single treatment course. In this review, we analyze recent progresses in the management of hemophilia and discuss opportunities and challenges.

Keywords

hemophilia A/B - gene therapy - factor VIII - factor IX
 

  • References

  • 1 Mannucci PM, Tuddenham EG. The hemophilias--from royal genes to gene therapy. N Engl J Med 2001; 344 (23) 1773-1779
    CrossrefPubMedGoogle Scholar
  • 2 Berntorp E, Shapiro AD. Modern haemophilia care. Lancet 2012; 379 (9824): 1447-1456
    CrossrefPubMedGoogle Scholar
  • 3 Melchiorre D, Linari S, Manetti M. , et al. Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A. Haematologica 2016; 101 (02) 219-225
    CrossrefPubMedGoogle Scholar
  • 4 Makris M, Oldenburg J, Mauser-Bunschoten EP, Peerlinck K, Castaman G, Fijnvandraat K. ; Subcommittee on Factor VIII, Factor IX and Rare Bleeding Disorders. The definition, diagnosis and management of mild hemophilia A: communication from the SSC of the ISTH. J ThrombHaemost 2018; 16 (12) 2530-2533
    CrossrefPubMedGoogle Scholar
  • 5 Pool JG, Gershgold EJ, Pappenhagen AR. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature 1964; 203: 312
    PubMedGoogle Scholar
  • 6 Soucie JM, Symons IV J, Evatt B, Brettler D, Huszti H, Linden J. ; Hemophilia Surveillance System Project Investigators. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia 2001; 7 (02) 198-206
    CrossrefPubMedGoogle Scholar
  • 7 Larsson SA, Wiechel B. Deaths in Swedish hemophiliacs, 1957-1980. Acta Med Scand 1983; 214 (03) 199-206
    PubMedGoogle Scholar
  • 8 Larsson SA. Life expectancy of Swedish haemophiliacs, 1831-1980. Br J Haematol 1985; 59 (04) 593-602
    CrossrefPubMedGoogle Scholar
  • 9 Ikkala E, Helske T, Myllylä G, Nevanlinna HR, Pitkänen P, Rasi V. Changes in the life expectancy of patients with severe haemophilia A in Finland in 1930-79. Br J Haematol 1982; 52 (01) 7-12
    CrossrefPubMedGoogle Scholar
  • 10 Smit C, Rosendaal FR, Varekamp I. , et al. Physical condition, longevity, and social performance of Dutch haemophiliacs, 1972-85. BMJ 1989; 298 (6668): 235-238
    CrossrefPubMedGoogle Scholar
  • 11 Chorba TL, Holman RC, Strine TW, Clarke MJ, Evatt BL. Changes in longevity and causes of death among persons with hemophilia A. Am J Hematol 1994; 45 (02) 112-121
    CrossrefPubMedGoogle Scholar
  • 12 Fischer K, van der Bom JG, Molho P. , et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia 2002; 8 (06) 745-752
    CrossrefPubMedGoogle Scholar
  • 13 Evatt BL, Gomperts ED, McDougal JS, Ramsey RB. Coincidental appearance of LAV/HTLV-III antibodies in hemophiliacs and the onset of the AIDS epidemic. N Engl J Med 1985; 312 (08) 483-486
    CrossrefPubMedGoogle Scholar
  • 14 Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia 2008; 14 (Suppl. 03) 10-18
    PubMedGoogle Scholar
  • 15 Oldenburg J, Dolan G, Lemm G. Haemophilia care then, now and in the future. Haemophilia 2009; 15 (Suppl. 01) 2-7
    CrossrefPubMedGoogle Scholar
  • 16 Soucie JM, Nuss R, Evatt B. , et al; The Hemophilia Surveillance System Project Investigators. Mortality among males with hemophilia: relations with source of medical care. Blood 2000; 96 (02) 437-442
    PubMedGoogle Scholar
  • 17 Chorba TL, Holman RC, Clarke MJ, Evatt BL. Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States. Am J Hematol 2001; 66 (04) 229-240
    CrossrefPubMedGoogle Scholar
  • 18 Wood WI, Capon DJ, Simonsen CC. , et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312 (5992): 330-337
    CrossrefPubMedGoogle Scholar
  • 19 Franchini M, Mannucci PM. Hemophilia A in the third millennium. Blood Rev 2013; 27 (04) 179-184
    CrossrefPubMedGoogle Scholar
  • 20 Grushin K, Miller J, Dalm D. , et al. Lack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIII. Haemophilia 2014; 20 (05) 723-731
    CrossrefPubMedGoogle Scholar
  • 21 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 9 (04) 418-435
    CrossrefPubMedGoogle Scholar
  • 22 Male C, Andersson NG, Rafowicz A. , et al; PedNetStudy Group. Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica 2020; (e-pub ahead of print) DOI: 10.3324/haematol.2019.239160.
    CrossrefPubMedGoogle Scholar
  • 23 Gringeri A, Mantovani LG, Scalone L, Mannucci PM. ; COCIS Study Group. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003; 102 (07) 2358-2363
    CrossrefPubMedGoogle Scholar
  • 24 Walsh CE, Jiménez-Yuste V, Auerswald G, Grancha S. The burden of inhibitors in haemophilia patients. ThrombHaemost 2016; 116 (Suppl. 01) S10-S17
    PubMedGoogle Scholar
  • 25 Giles AR, Mann KG, Nesheim ME. A combination of factor Xa and phosphatidylcholine-phosphatidylserine vesicles bypasses factor VIII in vivo. Br J Haematol 1988; 69 (04) 491-497
    CrossrefPubMedGoogle Scholar
  • 26 Ananyeva NM, Lee TK, Jain N, Shima M, Saenko EL. Inhibitors in hemophilia A: advances in elucidation of inhibitory mechanisms and in inhibitor management with bypassing agents. SeminThrombHemost 2009; 35 (08) 735-751
    PubMedGoogle Scholar
  • 27 Srivastava A, Brewer AK, Mauser-Bunschoten EP. , et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19 (01) e1-e47
    CrossrefPubMedGoogle Scholar
  • 28 Manco-Johnson MJ, Kempton CL, Reding MT. , et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J ThrombHaemost 2013; 11 (06) 1119-1127
    CrossrefPubMedGoogle Scholar
  • 29 Kavakli K, Yang R, Rusen L, Beckmann H, Tseneklidou-Stoeter D, Maas Enriquez M. ; LEOPOLD II Study Investigators. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J ThrombHaemost 2015; 13 (03) 360-369
    CrossrefPubMedGoogle Scholar
  • 30 Tagliaferri A, Feola G, Molinari AC. , et al; POTTER Study Group. Benefits of prophylaxis versus on-demand treatment in adolescents and adults with severe haemophilia A: the POTTER study. ThrombHaemost 2015; 114 (01) 35-45
    PubMedGoogle Scholar
  • 31 Valentino LA, Mamonov V, Hellmann A. , et al; Prophylaxis Study Group. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J ThrombHaemost 2012; 10 (03) 359-367
    CrossrefPubMedGoogle Scholar
  • 32 Gringeri A, Lundin B, von Mackensen S, Mantovani L, Mannucci PM. ; ESPRIT Study Group. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J ThrombHaemost 2011; 9 (04) 700-710
    CrossrefPubMedGoogle Scholar
  • 33 O'Hara J, Sima CS, Frimpter J, Paliargues F, Chu P, Presch I. Long-term outcomes from prophylactic or episodic treatment of haemophilia A: a systematic review. Haemophilia 2018; 24 (05) e301-e311
    CrossrefPubMedGoogle Scholar
  • 34 Hilliard P, Zourikian N, Blanchette V. , et al. Musculoskeletal health of subjects with hemophilia A treated with tailored prophylaxis: Canadian Hemophilia Primary Prophylaxis (CHPS) Study. J ThrombHaemost 2013; 11 (03) 460-466
    CrossrefPubMedGoogle Scholar
  • 35 Witmer C, Presley R, Kulkarni R, Soucie JM, Manno CS, Raffini L. Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. Br J Haematol 2011; 152 (02) 211-216
    CrossrefPubMedGoogle Scholar
  • 36 Tagliaferri A, Rivolta GF, Iorio A. , et al; Italian Association of Hemophilia Centers. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010; 16 (03) 437-446
    PubMedGoogle Scholar
  • 37 Triemstra M, Rosendaal FR, Smit C, Van der Ploeg HM, Briët E. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. Ann Intern Med 1995; 123 (11) 823-827
    PubMedGoogle Scholar
  • 38 Plug I, Van Der Bom JG, Peters M. , et al. Mortality and causes of death in patients with hemophilia, 1992-2001: a prospective cohort study. J ThrombHaemost 2006; 4 (03) 510-516
    CrossrefPubMedGoogle Scholar
  • 39 Darby SC, Kan SW, Spooner RJ. , et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007; 110 (03) 815-825
    PubMedGoogle Scholar
  • 40 Chang CY, Yeh GC, Lin SY, Tseng IJ, Tsai CH, Lee YW. Trends in the epidemiology, diagnosed age and mortality rate of haemophiliacs in Taiwan: a population-based study, 1997-2009. Haemophilia 2014; 20 (04) 535-540
    CrossrefPubMedGoogle Scholar
  • 41 Eckhardt CL, Loomans JI, van Velzen AS. , et al; INSIGHT Study Group. Inhibitor development and mortality in non-severe hemophilia A. J ThrombHaemost 2015; 13 (07) 1217-1225
    CrossrefPubMedGoogle Scholar
  • 42 Goel R, Krishnamurti L. Mortality, health care utilization and associated diagnoses in hospitalized patients with haemophilia in the United States: first reported nationwide estimates. Haemophilia 2012; 18 (05) 688-692
    CrossrefPubMedGoogle Scholar
  • 43 Lövdahl S, Henriksson KM, Baghaei F. , et al. Incidence, mortality rates and causes of deaths in haemophilia patients in Sweden. Haemophilia 2013; 19 (03) 362-369
    CrossrefPubMedGoogle Scholar
  • 44 Walsh CE, Soucie JM, Miller CH. ; United States Hemophilia Treatment Center Network. Impact of inhibitors on hemophilia A mortality in the United States. Am J Hematol 2015; 90 (05) 400-405
    CrossrefPubMedGoogle Scholar
  • 45 Yoo KY, Kim SK, Kwon SS. , et al. Life expectancy of Korean haemophiliacs, 1991-2012. Haemophilia 2014; 20 (04) e356-e358
    CrossrefPubMedGoogle Scholar
  • 46 Mansouritorghabeh H, Rahimi H, Mohades ST, Behboudi M. Causes of death among 379 patients with hemophilia: a developing country's report. Clin Appl ThrombHemost 2018; 24 (04) 612-617
    PubMedGoogle Scholar
  • 47 Loomans JI, Eckhardt CL, Reitter-Pfoertner SE. , et al. Mortality caused by intracranial bleeding in non-severe hemophilia A patients. J ThrombHaemost 2017; 15 (06) 1115-1122
    CrossrefPubMedGoogle Scholar
  • 48 Jardim LL, van der Bom JG, Caram-Deelder C, Gouw SC, Leal Cherchiglia M, Meireles Rezende S. Mortality of patients with haemophilia in Brazil: first report. Haemophilia 2019; 25 (03) e146-e152
    PubMedGoogle Scholar
  • 49 Callaghan MU, Sidonio R, Pipe SW. Novel therapeutics for hemophilia and other bleeding disorders. Blood 2018; 132 (01) 23-30
    PubMedGoogle Scholar
  • 50 Hart DP, Kessler CM, Aledort L. Re-personalization and stratification of hemophilia care in an evolving treatment landscape. Hematology 2019; 24 (01) 737-741
    CrossrefPubMedGoogle Scholar
  • 51 Oldenburg J. Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens. Blood 2015; 125 (13) 2038-2044
    CrossrefPubMedGoogle Scholar
  • 52 Ling M, Heysen JP, Duncan EM, Rodgers SE, Lloyd JV. High incidence of ankle arthropathy in mild and moderate haemophilia A. ThrombHaemost 2011; 105 (02) 261-268
    PubMedGoogle Scholar
  • 53 Soucie JM, Monahan PE, Kulkarni R, Konkle BA, Mazepa MA. ; US Hemophilia Treatment Center Network. The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B. Blood Adv 2018; 2 (16) 2136-2144
    CrossrefPubMedGoogle Scholar
  • 54 Aronstam A, Arblaster PG, Rainsford SG. , et al. Prophylaxis in haemophilia: a double-blind controlled trial. Br J Haematol 1976; 33 (01) 81-90
    CrossrefPubMedGoogle Scholar
  • 55 Nilsson IM, Hedner U, Ahlberg A. Haemophilia prophylaxis in Sweden. Acta PaediatrScand 1976; 65 (02) 129-135
    PubMedGoogle Scholar
  • 56 Iorio A, Iserman E, Blanchette V. , et al. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. Haemophilia 2017; 23 (03) e170-e179
    CrossrefPubMedGoogle Scholar
  • 57 Gouw SC, van der Bom JG, Ljung R. , et al; PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368 (03) 231-239
    CrossrefPubMedGoogle Scholar
  • 58 Peyvandi F, Mannucci PM, Garagiola I. , et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 2016; 374 (21) 2054-2064
    CrossrefPubMedGoogle Scholar
  • 59 Oldenburg J, Austin SK, Kessler CM. ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective. Haemophilia 2014; 20 (Suppl. 06) 17-26
    CrossrefPubMedGoogle Scholar
  • 60 Gringeri A. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study. Haemophilia 2007; 13 (Suppl. 05) 73-77
    CrossrefPubMedGoogle Scholar
  • 61 Kitazawa T, Esaki K, Tachibana T. , et al. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens. ThrombHaemost 2017; 117 (07) 1348-1357
    PubMedGoogle Scholar
  • 62 Oldenburg J, Mahlangu JN, Kim B. , et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377 (09) 809-818
    CrossrefPubMedGoogle Scholar
  • 63 Young G, Liesner R, Chang T. , et al. A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 2019; 134 (24) 2127-2138
    CrossrefPubMedGoogle Scholar
  • 64 Mahlangu J, Oldenburg J, Paz-Priel I. , et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018; 379 (09) 811-822
    CrossrefPubMedGoogle Scholar
  • 65 Sehgal A, Barros S, Ivanciu L. , et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 2015; 21 (05) 492-497
    CrossrefPubMedGoogle Scholar
  • 66 Bolliger D, Szlam F, Suzuki N, Matsushita T, Tanaka KA. Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice. ThrombHaemost 2010; 103 (06) 1233-1238
    PubMedGoogle Scholar
  • 67 Safdar H, Cheung KL, Salvatori D. , et al. Acute and severe coagulopathy in adult mice following silencing of hepatic antithrombin and protein C production. Blood 2013; 121 (21) 4413-4416
    CrossrefPubMedGoogle Scholar
  • 68 Pasi KJ, Rangarajan S, Georgiev P. , et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med 2017; 377 (09) 819-828
    CrossrefPubMedGoogle Scholar
  • 69 Pasi KJ, Georgiev P, Mant T. , et al. Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia: updated results from a phase 1 and phase 1/2 extension study in patients with inhibitors. Blood 2016; 128 (22) 1397
    CrossrefPubMedGoogle Scholar
  • 70 Hemophilia WFo. Update: FDA lifts suspension of fitusiran trial [cited 2018 6 March]. Available at: https://news.wfh.org/update-fda-lifts-suspension-fitusiran-trial/
    PubMedGoogle Scholar
  • 71 Hilden I, Lauritzen B, Sørensen BB. , et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood 2012; 119 (24) 5871-5878
    CrossrefPubMedGoogle Scholar
  • 72 Shapiro AD, Angchaisuksiri P, Astermark J. , et al. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood 2019; 134 (22) 1973-1982
    PubMedGoogle Scholar
  • 73 Rangarajan S, Walsh L, Lester W. , et al. AAV5–factor VIII gene transfer in severe hemophilia A. N Engl J Med 2017; 377 (26) 2519-2530
    CrossrefPubMedGoogle Scholar
  • 74 Nathwani AC, Reiss UM, Tuddenham EG. , et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371 (21) 1994-2004
    CrossrefPubMedGoogle Scholar
  • 75 Nathwani AC, Tuddenham EG, Rangarajan S. , et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365 (25) 2357-2365
    CrossrefPubMedGoogle Scholar
  • 76 McIntosh J, Lenting PJ, Rosales C. , et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood 2013; 121 (17) 3335-3344
    CrossrefPubMedGoogle Scholar
  • 77 Miesbach W, Meijer K, Coppens M. , et al. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood 2018; 131 (09) 1022-1031
    CrossrefPubMedGoogle Scholar
  • 78 Jennings I, Kitchen DP, Woods TAL, Kitchen S, Walker ID, Preston FE. Laboratory performance in the World Federation of Hemophilia EQA programme, 2003-2008. Haemophilia 2009; 15 (02) 571-577
    CrossrefPubMedGoogle Scholar
  • 79 Potgieter JJ, Damgaard M, Hillarp A. One-stage vs. chromogenic assays in haemophilia A. Eur J Haematol 2015; 94 (Suppl. 77) 38-44
    CrossrefPubMedGoogle Scholar
  • 80 Teichman J, Chaudhry HR, Sholzberg M. Novel assays in the coagulation laboratory: a clinical and laboratory perspective. Transfus Apheresis Sci 2018; 57 (04) 480-484
    CrossrefPubMedGoogle Scholar
  • 81 Moser KA, Adcock Funk DM. Chromogenic factor VIII activity assay. Am J Hematol 2014; 89 (07) 781-784
    CrossrefPubMedGoogle Scholar
  • 82 Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J ThrombHaemost 2016; 14 (02) 248-261
    CrossrefPubMedGoogle Scholar
  • 83 Kitchen S, Kershaw G, Tiefenbacher S. Recombinant to modified factor VIII and factor IX - chromogenic and one-stage assays issues. Haemophilia 2016; 22 (Suppl. 05) 72-77
    PubMedGoogle Scholar
  • 84 Bowyer AE, Hillarp A, Ezban M, Persson P, Kitchen S. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study. J ThrombHaemost 2016; 14 (07) 1428-1435
    CrossrefPubMedGoogle Scholar
  • 85 Shima M, Hanabusa H, Taki M. , et al. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv 2017; 1 (22) 1891-1899
    CrossrefPubMedGoogle Scholar
  • 86 Al-Samkari H, Croteau SE. Shifting landscape of hemophilia therapy: implications for current clinical laboratory coagulation assays. Am J Hematol 2018; 93 (08) 1082-1090
    CrossrefPubMedGoogle Scholar
  • 87 Müller J, Pekrul I, Pötzsch B, Berning B, Oldenburg J, Spannagl M. Laboratory monitoring in emicizumab-treated persons with hemophilia A. ThrombHaemost 2019; 119 (09) 1384-1393
    PubMedGoogle Scholar
  • 88 National Hemophilia Foundation. MASAC Safety Information Update on Emicizumab (HEMLIBRA) 2018. Available at: https://www.hemophilia.org/Newsroom/Medical-News/MASAC-Safety-Information-Update-on-Emicizumab-HEMLIBRA . Accessed May 27, 2020
    PubMedGoogle Scholar
  • 89 Dargaud Y, Lienhart A, Janbain M, Le Quellec S, Enjolras N, Negrier C. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. Haematologica 2018; 103 (04) e181-e183
    CrossrefPubMedGoogle Scholar
  • 90 Calatzis AKN, Levy G, Adamkewitcz J. , Eds. Effect of emicizumab – a humanized bispecific antibody mimicking FVIII cofactor function – on a variety of assay systems [Abstract]. Paper presented at: European Congress on Thrombosis and Haemostasis Abstract; 2016; The Hague
    PubMedGoogle Scholar
  • 91 Chowdary P, Lethagen S, Friedrich U. , et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost 2015; 13 (05) 743-754
    CrossrefPubMedGoogle Scholar
  • 92 Chitlur M, Rivard GE, Lillicrap D, et al. Recommendations for Performing Thromboelastography/Thromboelastometry in Hemophilia: Communication From the SSC of the ISTH. J Thromb Haemost 2014;12(01):103–106
    PubMed